A Clinical Trial Study of Hip System in Primary Total Hip Arthroplasty in China

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-06-07

Study Completion Date

2018-01-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A clinical trial of total Hip system used in Primary Total Hip Arthroplasty in China.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Safety and Efficacy of OR3O™ Dual Mobility System vs. Conventional Single Bearing Design Total Hip System

NCT04941729

Degenerative Hip Joint Disease Rheumatoid Arthritis (RA) Femoral Neck Fractures +4 more

TERMINATED NA

A Multi-centre Study to Assess the Long-term Performance of the Summit™ Hip in Primary Total Hip Replacement

NCT00208390

Rheumatoid Arthritis Osteoarthritis Post-traumatic Arthritis +6 more

TERMINATED PHASE4

Analysis of Influencing Factors and Construction of Prediction Models of Artificial Joint Replacement in China

NCT05170321

Knee Arthropathy Hip Arthropathy Shoulder Arthropathy +2 more

UNKNOWN

PMCF Study of MOTIVATION HIP System in THA

NCT03892005

Total Hip Arthroplasty

SUSPENDED

Robot Assisted Total Hip Arthroplasties

NCT05947734

Hip Arthropathy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A Prospective, Randomized, Multicenter, Controlled Study Comparing the Outcomes of Primary Total Hip Arthroplasty Devices Manufactured in China versus Devices Manufactured Outside of China

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis Congenital Hip Dysplasia Avascular Necrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Total Hip System made in China

Patient in this arm will be implanted with Primary Total Hip Arthroplasty Devices Manufactured in China

Group Type EXPERIMENTAL

Total Hip System made in China (SUN, CoCr, Duraloc, Marathon)

Intervention Type DEVICE

SUN Hip stem,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)

Total Hip System made outside of China

Patient in this arm will be implanted with Primary Total Hip Arthroplasty Devices Manufactured Outside of China

Group Type ACTIVE_COMPARATOR

Total Hip System made outside of China (Summit, CoCr, Duraloc, Marathon)

Intervention Type DEVICE

Summit Porocoat STD,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Total Hip System made in China (SUN, CoCr, Duraloc, Marathon)

SUN Hip stem,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)

Intervention Type DEVICE

Total Hip System made outside of China (Summit, CoCr, Duraloc, Marathon)

Summit Porocoat STD,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The subject is ≥55, and ≤80 years old
2. The Subject must be of Chinese ethnic descent and be willing to return on three occasions for clinical evaluations.
3. Subject is a suitable candidate for primary total hip replacement using the devices described in this CIP
4. Subject must meet all criteria specified in BOTH SUN hip stem and Summit hip stem instructions for use (IFU)
5. Before surgery, subject is willing and able to sign the informed consent form approved by the Institutional Review Board (IRB), Ethics Committee (EC) or Ethical Review Board (ERB).
6. Subject, in the opinion of the Clinical Investigator, is able to understand this clinical investigation and co-operate with investigational procedures.
7. Subject must be comfortable with speaking, reading, and understanding questions and providing responses in an available translated language for the patient reported outcomes (PROs) in the CIP.
8. Subject is receiving a unilateral hip replacement or, if a contralateral hip replacement is anticipated, the surgery must occur within 6 months of the first study hip. The second hip will not be enrolled in the study.

Exclusion Criteria

1. Subject does not provide written voluntary consent to participate in the clinical study.
2. The Subject is a woman who is pregnant or lactating.
3. Subjects who have undergone THA in contralateral hip within the past 6 months.
4. Contralateral hip has been enrolled in the study.
5. Presence of any previous prosthetic hip replacement device in affected hip.
6. Previous Girdlestone procedure (resection arthroplasty) or surgical fusion of the affected hip
7. Subject has hip dysplasia CROWE classification grade of 3 or 4.
8. Above knee amputation of either contralateral or ipsilateral leg
9. Subject is anticipated to require a contralateral THA between 6 months and 1-year.
10. Subject has an active infection
11. Subject has a malignant disease, severe condition, alcohol or drug addiction and/or mental disorders that the investigator believes will interfere with the study participation.
12. Subjects with severe osteoporosis, metabolic bone disease, radioactive bone disease or tumor in the bone surrounding the hip joint that, in the opinion of the investigator, will negatively impact implant fixation and the outcome of the investigation;
13. Subject has significant neurological or musculoskeletal disorders or disease that may adversely affect gait or weight bearing (e.g. muscular dystrophy, multiple sclerosis, cerebral infarction, hemiplegia, Charcot disease).
14. Subject is not comfortable with speaking, reading, and understanding questions and providing responses in an available translated language for the PROs in the CIP.
15. Subject has a medical condition with less than 2 years of life expectancy due to other medical conditions.
16. The patient has comorbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study.
17. The patient is currently participating in another investigational drug or device study.
18. Subject is a prisoner.
19. Subject has a known allergy to any component of the implant (metal for example).

Minimum Eligible Age

55 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No